Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Decreases By 72.9%

Key Points

• Short interest in Inventiva S.A. has fallen by 72.9%, dropping from 36,900 shares to 10,000 shares by the end of July, indicating a potential shift in investor sentiment.
• A hedge fund, Wealth Enhancement Advisory Services LLC, recently acquired a stake in Inventiva, purchasing 10,715 shares valued at around $32,000.
• Despite these developments, Inventiva's stock is down 3.6% amidst regular trading, reaching $4.07, although it has a 52-week range between $1.53 and $4.36.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) was the target of a large decrease in short interest in the month of July. As of July 31st, there was short interest totaling 10,000 shares, adecreaseof72.9% from the July 15th total of 36,900 shares. Currently,0.0% of the company's shares are short sold. Based on an average daily volume of 20,800 shares, the days-to-cover ratio is presently 0.5 days. Based on an average daily volume of 20,800 shares, the days-to-cover ratio is presently 0.5 days. Currently,0.0% of the company's shares are short sold.

Institutional Trading of Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,715 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

Inventiva Stock Performance

NASDAQ:IVA traded up $0.13 on Wednesday, reaching $4.58. 29,393 shares of the stock traded hands, compared to its average volume of 17,825. The company's 50 day moving average is $3.38 and its 200-day moving average is $3.22. Inventiva has a 1-year low of $1.53 and a 1-year high of $4.64.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.